Cushings Disease
Endocrinology
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NovartisLCI699
RecordatiPasireotide
Clinical Trials (2)
Total enrollment: 183 patients across 2 trials
Safety and Efficacy of LCI699 in Cushing's Disease Patients
Start: Mar 2011Est. completion: Oct 201931 patients
Phase 2Completed
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Start: Mar 2013Est. completion: Jul 2023152 patients
N/ACompleted
Related Jobs in Endocrinology
Research Associate I/II - Biology
Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr
Associate Director, Clinical Operations
Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr
Associate Director/Director, Regulatory Affairs
Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr
Medical Science Liaison (rare diseases)
Amgen
Poland - Lódz
1mo ago
Senior/Executive Director, Analytical Development
Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr
Senior Clinical Scientist - Job ID: 1845
Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Peptide is the dominant modality (100% of programs)
2 companies competing in this space